Hope Is Not a Workflow, Spring 2026
Hope Is Not a Workflow, Spring 2026 centered on honest discussion about where the cell and gene therapy industry stands today, and what continues to limit broader patient access despite significant scientific progress. Conversations throughout the meeting reflected lived experience, detailing what is working, where friction still persists, and how the operational realities of the real-world shape the pace of adoption.
Cryoport Systems was honored to participate in this event, both joining a panel discussion and with a dedicated presentation. Together, these sessions addressed recurring themes raised across the meeting, including gaps in education, access constraints, cost pressure, and the growing need for operational readiness and consistency as programs scale globally.
Participating in the conversations throughout the event offered an opportunity to share perspectives across development stages and regions, while engaging directly with peers who are navigating similar challenges. These discussions reinforced the value of grounding industry progress in practical execution, not in innovation alone.
Takeaways from Hope Is Not a Workflow 2026
Panel Discussion
What Will It Take to Move Cell Therapy Forward? Reflections from the Hope Is Not a Workflow Panel
At the recent Hope Is Not a Workflow event, industry leaders came together to tackle some of the most persistent questions facing cell and gene therapy today. During a panel, Dominic Clarke (VP, IntegriCell® Technical Operations, Cryoport Systems) joined the discussion to share his perspective on what is slowing adoption and what it will take to move the industry forward in a meaningful way. The discussion didn’t point to a single, easy answer. Instead, the trend that emerged was a set of interconnected challenges around education, access, cost, and collaboration that continue to shape how therapies reach patients.
Presentation
Building Global Readiness: Key Takeaways from Matthew Frazzetta at Hope Is Not a Workflow
As cell and gene therapies advance scientifically, operational readiness is increasingly determining whether those therapies reach patients at scale. During a presentation at Hope Is Not a Workflow, Matthew Frazzetta addressed the question: How do we build a global, standardized, and scalable supply chain capable of supporting the next generation of advanced therapies? Matthew made the case that global readiness, while often treated as an operational afterthought, is actually a strategic requirement that must be designed into therapies from an early stage if the industry is serious about broad patient access.
Industry Insights
Article: Building Investor Confidence Through an Intentional Supply Chain Strategy
In early investment conversations, scientific innovation used to carry most of the weight. In today’s funding environment, however, that has shifted. Today, investors quickly move past the science and begin investigating whether a program can operate with the discipline and scalability required to grow. They’re looking more closely at operational details from an earlier stage, including whether the foundational systems being put in place now can carry the weight of future global commercialization. Readiness is no longer something teams can build later. Instead, it is increasingly assessed from the moment conversations begin.
Thank you to those who engaged with us during Hope Is Not a Workflow, Spring 2026.
We appreciated the opportunity to contribute to the discussions that were honest about the challenges the industry continues to face and how progress can be made. These conversations highlighted the importance of moving beyond dialogue alone and continuing to translate lessons learned into tangible improvements in how therapies are delivered to patients. We value the chance to be part of these discussions and look forward to continuing them throughout the year.
-
Matthew Frazzetta
Vice President – Global Accounts, Bioservices -
Dominic Clarke
Vice President – Technical Operations IntegriCell™
About Cryoport Systems
Cryoport Systems is a comprehensive supply chain partner for the life sciences industry focused on meeting the challenges of the global cell and gene therapy market. We excel in the specialized management of the biopharma supply chain through our comprehensive offerings in logistics, BioServices and biostorage, cryopreservation, and consulting. With our expansive platform and decades of temperature-controlled supply chain expertise, Cryoport Systems helps Enable the Outcome™ for advanced therapies programs, safely and securely guiding critical therapies to patients in need.
About the Conference
The Hope Is Not a Workflow symposium brings together leaders across the cell and gene therapy (CGT) ecosystem to discuss the practical challenges of scaling advanced therapies from discovery to commercialization. The event features expert presentations, rapid-fire sessions, and panel discussions focused on manufacturing, collaboration, and data-driven approaches to improving CGT production. Participants include developers, technology providers, and industry innovators sharing real-world insights and solutions for accelerating therapeutic development. Overall, the event emphasizes moving beyond optimism to actionable strategies that improve scalability, efficiency, and clinical impact in the CGT industry.
Let’s Connect
Interested in setting up a time to talk with our team of experts? Looking to follow up on a recent presentation or booth conversation? We’d love to hear from you! Fill out the form below and our team will be in touch.